EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs

Nicholas C Borgogna, Tyler Owen, Jacob Vaughn, David A L Johnson, Stephen L Aita, Benjamin D Hill

European Journal of Psychotraumatology · 31.12.2024 · 15 (1)

DOI: 10.1080/20008066.2023.2299124 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Psychotraumatology, online erschienen am 15.01.2024. Verfasst von Nicholas C Borgogna und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Sciences, Texas Tech University, Lubbock, TX, USA. Hauptthemen laut MEDLINE: Ketamine, Stress Disorders, Post-Traumatic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Texas Tech University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PTSD is a significant mental health problem worldwide. Current evidence-based interventions suffer various limitations. Ketamine is a novel agent that is hoped to be incrementally better than extant interventions.

Objective

Several randomized control trials (RCTs) of ketamine interventions for PTSD have now been published. We sought to systematically review and meta-analyse results from these trials to evaluate preliminary evidence for ketamine's incremental benefit above-and-beyond control interventions in PTSD treatment.

Results

Omnibus findings from 52 effect sizes extracted across six studies (n = 221) yielded a small advantage for ketamine over control conditions at reducing PTSD symptoms (g = 0.27, 95% CI = 0.03, 0.51). However, bias-correction estimates attenuated this effect (adjusted g = 0.20, 95%, CI = -0.08, 0.48). Bias estimates indicated smaller studies reported larger effect sizes favouring ketamine. The only consistent timepoint assessed across RCTs was 24-hours post-initial infusion. Effects at 24-hours post-initial infusion suggest ketamine has a small relative advantage over controls (g = 0.35, 95% CI = 0.06, 0.64). Post-hoc analyses at 24-hours post-initial infusion indicated that ketamine was significantly better than passive controls (g = 0.44, 95% CI = 0.03, 0.85), but not active controls (g = 0.24, 95% CI = -0.30, 0.78). Comparisons one-week into intervention suggested no meaningful group differences (g = 0.24, 95% CI = 0.00, 0.48). No significant differences were evident for RCTs that examined effects two-weeks post initial infusion (g = 0.17, 95% CI = -0.10, 0.44).

Conclusions

Altogether, ketamine-for-PTSD RCTs reveal a nominal initial therapeutic advantage relative to controls. However, bias and heterogeneity appear problematic. While rapid acting effects were observed, all control agents (including saline) also evidenced rapid acting effects. We argue blind penetration to be a serious concern, and that placebo is the likely mechanism behind reported therapeutic effects. We systematically reviewed and meta-analysed all randomized control trials of ketamine intervention for PTSD.While ketamine was associated with a reduction in symptoms, the effect was generally not stronger than control conditions.By two-weeks post-initial infusion, no meaningful differences are evident between ketamine and controls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineStress Disorders, Post-TraumaticHumansQuality of Life

Stichwörter der Autor:innen

KetaminaKetaminePTSDTEPTbiasensayos de control aleatorizadosmeta-analysismetanalisisrandomized control trialssesgo

Substanzen

Ketamine

Autor:innen und Institutionen

  • Department of Psychological Sciences, Texas Tech University, Lubbock, TX, USA.
  • Veterans Affairs Maine Healthcare System, Augusta, ME, USA.
  • Department of Psychology, University of South Alabama, Mobile, AL, USA.

Förderung

  • Texas Tech University

Zitieren

APA

Borgogna, N. C., Owen, T., Vaughn, J., Johnson, D. A. L., Aita, S. L., & Hill, B. D. (2024). So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs. European Journal of Psychotraumatology, 15(1). https://doi.org/10.1080/20008066.2023.2299124

Vancouver

Borgogna NC, Owen T, Vaughn J, Johnson DAL, Aita SL, Hill BD. So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs. European Journal of Psychotraumatology. 2024;15(1). doi:10.1080/20008066.2023.2299124

BibTeX
@article{Borgogna2024,
  author = {Borgogna, Nicholas C and Owen, Tyler and Vaughn, Jacob and Johnson, David A L and Aita, Stephen L and Hill, Benjamin D},
  title = {So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs},
  journal = {European Journal of Psychotraumatology},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1080/20008066.2023.2299124}
}
Kostenlos starten →